Fragment-based drug design (FBDD) has become an increasingly popular platform for the identification of lead candidates in drug discovery programs, with surface plasmon resonance (SPR) becoming a core technology in many pharma and biotech settings for the identification of low-affinity fragment compounds.
ForteBio has recently introduced the next generation in SPR biosensor analysis for fragments, exclusively available on Pioneer systems. This Next Generation SPR consists of OneStep® and NeXtStep™ gradient injection technologies.
下载这个程序lication note to learn about ForteBio's Next Generation SPR, including:
Technology Networks Limited
Woodview | Bull Lane Industrial Estate | Sudbury | C010 0FD | UK
Email: privacy@technologynetworks.com
© 2020 Technology Networks. All rights reserved
Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out ourPrivacy Policy